LY2109761, a kinase inhibitor that blocks TβRI and TβRII kinase, can inhibit tumor growth and progression of hepatocellular carcinoma in vivo by blocking TGF-β dependent production of CTGF and CAF proliferation [102] (Table 1). This evidence concerns the gene CCN2 and neoplasm.